SEARCH BY NAME

BROWSE

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

SIENNA CANCER DIAGNOSTICS LIMITED (SDX)

Delisted from ASX 29/07/2020

SHARE PRICES

(discontinued 17 July 2020)

Former (or subsequent) names

 

Shareholder links

Our website ranking of SDX: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Link Market Services, Tower 4, 727 Collins Street Docklands VIC 3008
Tel : +61 3 9615 9800
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: 23 Normanby Rd Notting Hill, Victoria 3168
Tel:  03 8288 2141 Fax: 03 8288 2059

Date first listed: 03/08/2017
Company Secretary: Tony Di Pietro
Sector: Pharmaceuticals, Biotechnology & Life Sciences
Industry Group: 
Activities: Biotechnology and life science

delisted from the close of trading on Wednesday, 29 July 2020, pursuant to Listing rule 17.11.

29/07/2020

we understand BARD1 Life Sciences was successful with an offer of 13 new ordinary shares in BARD1 for every 5 Sienna shares

29/07/2020

The scheme of arrangement between Sienna and its shareholders in relation to the acquisition of all shares in Sienna by BARD1 Life Sciences was implemented today. This follows approval by shareholders on 15 July 2020 and approval of the scheme by the Federal Court of Australia on 20 July 2020. Eligible former Sienna shareholders have been issued 13 new ordinary shares in BARD1 for every 5 Sienna shares they held as at the Scheme record date being 23 July 2020.

28/07/2020

The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation at the close of trading today, Monday, 20 July 2020, in accordance with Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which BARD1 Life Sciences Limited will acquire all of the issued shares in SDX.

20/07/2020

The suspension of trading in the securities of Sienna Cancer Diagnostics Limited will be lifted immediately, following the release by SDX of an announcement regarding a capital raising.

29/11/2019

Sienna to raise up to approximately $4.2 million, before costs, via a share placement and rights issue at 3.5 cents per share. Issue price of 3.5 cents per share represents a 20% discount to the 30-day Volume Weighted Average Price (VWAP) of Sienna's shares traded on the ASX as at 25 November 2019, and a 13% premium to the last traded price of Sienna shares (being 3.1 cents on 25 November 2019). Funds will be used for further development of SIEN NETTM, co-development expenditures for the collaborative agreements with Minomic International Ltd and VivaZome Therapeutics Pty Ltd, and continued evaluation of potential technologies for acquisition or in-license.

29/11/2019

The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement regarding a capital raising.

28/11/2019

listed entity carried for record purposes only

03/08/2017

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    13/09/2017John Chiplin75,000$0.140$10,500

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Helen FisherIndependent Director28/03/2018
    Philip PowellNon Exec Director28/07/2020
    Geoffrey CummingNon Exec Director27/01/2006

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Tony Di PietroExecutive Director, CFO01/11/201428/07/2020
    Carl StubbingsExecutive Director, CEO31/12/201128/07/2020
    David EarpNon Exec Director01/12/201214/11/2019
    Matthew HoskinCEO04/02/201416/10/2019
    John ChiplinNon Exec Director22/01/201630/09/2018

    Date of first appointment, title may have changed.